A Phase 3 interventional study of Rotigotine and Rotigotine in Parkinson's Disease, sponsored by UCB Pharma. Completed at 77 sites in 5 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2014-10-27.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.
Among the 44 studies testing rotigotine in Parkinson Disease, this one has the largest enrollment of the 42 interventional ones that give a count, is one of 6 that started in 2007, is one of 20 in phase 3, and was the 12th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
Browse Parkinson Disease studies →1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:
Eva Pharma
Ages 30+
rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 22 · Phase 4 8
First in 1999; this study’s year is marked. 6 started in 2007.
This study's enrollment of 514 is above the median of 40 across 3,355 interventional studies indexed under Parkinson Disease.
Median enrollment 123 across the 42 interventional studies. Of the 41 that completed or were terminated, 30 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
44 studies in Parkinson Disease by UCB S.A.: none open now, none under way, none of them phase 3. Of 44 finished, 29 (66%) have results posted.
Among the 44 studies in Parkinson Disease by UCB S.A., this one has the largest enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2007, is one of 19 in phase 3, and was the 14th registered.
UCB S.A.’s Parkinson Disease studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing rotigotine in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 44 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to show Rotigotine dose response at four doses of Rotigotine used with L-dopa in treating advanced stage Parkinson's disease.
To maintain treatment blind, two different active patch sizes were used (10 cm\^2 \& 20 cm\^2). Placebo patches matched according to size and appearance. During the trial subjects applied up to three patches, active and placebo, to achieve their assigned daily dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Rotigotine
Drug: Rotigotine
Drug: Rotigotine
Drug: Rotigotine
Other: Placebo
2 mg/24 hr (one 10 cm\^2) transdermal patch applied daily for titration and maintenance period - 16 weeks
Also known as: Neupro
4 mg/24 hr (one 20 cm\^2) transdermal patch applied daily for titration and maintenance period - 16 weeks
Also known as: Neupro
Placebo transdermal patch applied daily
6 mg/24 hr (one 10 cm\^2 \& one 20 cm\^2) transdermal patches applied daily for titration and maintenance period - 16 weeks
Also known as: Neupro
8 mg/24 hr (two 10 cm\^2 \& one 20 cm\^2) transdermal patches applied daily for titration and maintenance period - 16 weeks
Also known as: Neupro
The Change in the Absolute Time Spent "Off" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary
Time "Off" is defined as when the patient does not have the effect of anti-Parkinson's medication.
Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
The Change in Relative Time Spent "Off" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary
Time "Off" is defined as when the patient does not have the effect of anti-Parkinson's medication.
Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
The Change in the Absolute Time Spent "on" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary
Time "On" is defined as when the patient has the effect of anti-Parkinson's medication.
Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
The Change in the Relative Time Spent "on" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary
Time "On" is defined as when the patient has the effect of anti-Parkinson's medication.
Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
The Change in the Status of the Subject After Wake-Up From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary
Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II From Baseline to the End of the Maintenance Period
The Unified Parkinson's Disease Rating Scale (UPDRS) Part II is a scale for the assessment of function in Parkinson's disease. UPDRS Part II measures Activities of Daily Living. It consists of 13 questions, each ranging from 0 to 4. The sum score of the UPDRS Part II ranges from 0 to 52. A higher score indicates greater disability. A negative change score indicates improvement.
Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III From Baseline to the End of the Maintenance Period
The Unified Parkinson's Disease Rating Scale (UPDRS) Part III is a scale for the assessment of function in Parkinson's disease. UPDRS Part III measures Motor Function. It consists of 14 items with 27 questions, each ranging from 0 to 4. The sum score for the UPDRS Part III ranges from 0 to 108. A higher score indicates greater disability. A negative change score indicates improvement.
Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - What Proportion of the Waking Day Are Dyskinesias Present?
Item = Duration (question #32) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period - What proportion of the waking day are dyskinesias present? Has a possible score of 0 - 4 points (4 = maximum). A higher score indicates more severe symptoms. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.
Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Disability: How Disabling Are the Dyskinesias?
Item = Disability (question #33) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period - How disabling are the dyskinesias? Has a possible score of 0 - 4 points (4 = maximum). A higher score indicates more severe symptoms. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.
Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Painful Dyskinesias: How Painful Are the Dyskinesias?
Item = Painful Dyskinesia (question #34) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period - How painful are the dyskinesias? Has a possible score of 0 - 4 points (4 = maximum). A higher score indicates more severe symptoms. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.
Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Presence of Early Morning Dystonia
Item = Presence of Early Morning Dystonia (question #35) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates early morning dystonia. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.
Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Are "Off" Periods Predictable?
Item = Are "off" periods predictable (question #36) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates "off" periods are predictable. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.
Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Are "Off" Periods Unpredictable?
Item = Are "off" periods unpredictable (question #37) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates "off" periods are unpredictable. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.
Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Do "Off" Periods Come on Suddenly?
Item = Do "off" periods come on suddenly, within a few seconds (question #38) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates "off" periods come on suddenly, within a few seconds. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.
Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - What Proportion of the Waking Day is the Subject "Off", on Average?
Item = What proportion of the waking day is the subject "off", on average (question #39) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 - 4 points (4 = maximum). A higher score indicates the subject is "off" a larger portion of the waking day. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.
Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Does the Patient Have Anorexia, Nausea, or Vomiting?
Item = Does the patient have anorexia, nausea, or vomiting (question #40) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates subject has anorexia, nausea, or vomiting. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.
Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Does the Patient Have Any Sleep Disturbances Such as Insomnia or Hypersomnolence?
Item = Does the patient have any sleep disturbances such as insomnia or hypersomnolence (question #41) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates subject has sleep disturbances such as insomnia or hypersomnolence. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.
Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV From Baseline to the End of the Maintenance Period - Does the Patient Have Symptomatic Orthostasis?
Item = Does the patient have symptomatic orthostasis (question #42) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates subject has symptomatic orthostasis. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.
Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
The Change in Number of "Off" Periods From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary
Time "Off" is defined as when the patient does not have the effect of anti-Parkinson's medication.
Time frame: From Baseline to the End of the Maintenance Period [16 Weeks Treatment Period (4 weeks Titration Period and 12 weeks Maintenance Period)].
This Phase III study started in July 2007 with subjects from the United States, Mexico, Peru, Chile, and India. The primary completion date and study completion date occurred in July 2011. The Participant Flow and Baseline Characteristics are represenative of the Safety Set (SS), which is 514 subjects.
| Milestone | Rotigotine 2 mg/24 hr | Rotigotine 4 mg/24 hr | Rotigotine 6 mg/24 hr | Rotigotine 8 mg/24 hr | Placebo |
|---|---|---|---|---|---|
| Started | 101 | 107 | 104 | 94 | 108 |
| Completed | 79 | 84 | 82 | 80 | 81 |
| Not completed | 22 | 23 | 22 | 14 | 27 |
| Withdrew: Adverse event | 12 | 15 | 12 | 5 | 17 |
| Withdrew: Lack of efficacy | 3 | 0 | 2 | 2 | 7 |
| Withdrew: Withdrawal by subject | 2 | 3 | 1 | 2 | 0 |
| Withdrew: Protocol violation | 1 | 1 | 2 | 0 | 0 |
| Withdrew: Unsatisfactory subject compliance | 1 | 2 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 4 | 2 | 2 |
| Withdrew: Randomization error | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Dispensing error | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Subject moved | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Sponsor request | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Family problem | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Site closed | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Subject withdrawal | 0 | 0 | 0 | 1 | 0 |
Time "Off" is defined as when the patient does not have the effect of anti-Parkinson's medication.
| Hours | Rotigotine 2 mg/24 hr | Rotigotine 4 mg/24 hr | Rotigotine 6 mg/24 hr | Rotigotine 8 mg/24 hr | Placebo |
|---|---|---|---|---|---|
| The Change in the Absolute Time Spent "Off" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary | -1.948 ± 2.587 | -2.052 ± 3.113 | -2.138 ± 2.721 | -2.360 ± 2.608 | -1.499 ± 3.062 |
Time "Off" is defined as when the patient does not have the effect of anti-Parkinson's medication.
| Hours | Rotigotine 2 mg/24 hr | Rotigotine 4 mg/24 hr | Rotigotine 6 mg/24 hr | Rotigotine 8 mg/24 hr | Placebo |
|---|---|---|---|---|---|
| The Change in Relative Time Spent "Off" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary | -12.058 ± 16.517 | -13.463 ± 20.099 | -13.410 ± 17.202 | -14.529 ± 16.531 | -9.250 ± 18.942 |
Time "On" is defined as when the patient has the effect of anti-Parkinson's medication.
| Hours | Rotigotine 2 mg/24 hr | Rotigotine 4 mg/24 hr | Rotigotine 6 mg/24 hr | Rotigotine 8 mg/24 hr | Placebo |
|---|---|---|---|---|---|
| The Change in the Absolute Time Spent "on" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary | 1.821 ± 2.655 | 2.095 ± 3.120 | 2.118 ± 2.827 | 2.364 ± 2.876 | 1.335 ± 2.975 |
Time "On" is defined as when the patient has the effect of anti-Parkinson's medication.
| Hours | Rotigotine 2 mg/24 hr | Rotigotine 4 mg/24 hr | Rotigotine 6 mg/24 hr | Rotigotine 8 mg/24 hr | Placebo |
|---|---|---|---|---|---|
| The Change in the Relative Time Spent "on" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary | 12.058 ± 16.517 | 13.463 ± 20.099 | 13.410 ± 17.202 | 14.529 ± 16.531 | 9.250 ± 18.942 |
| Hours | Rotigotine 2 mg/24 hr | Rotigotine 4 mg/24 hr | Rotigotine 6 mg/24 hr | Rotigotine 8 mg/24 hr | Placebo |
|---|---|---|---|---|---|
| ON Without Troublesome Dyskinesias | 23.688 ± 41.607 | 24.593 ± 43.006 | 20.935 ± 42.132 | 21.083 ± 45.642 | 19.712 ± 41.857 |
| ON With Troublesome Dyskinesias | -0.667 ± 18.874 | -0.813 ± 12.804 | 1.626 ± 23.659 | 1.667 ± 13.417 | -0.206 ± 8.934 |
| OFF | -23.021 ± 40.667 | -23.780 ± 43.150 | -22.561 ± 40.519 | -22.750 ± 47.193 | -19.506 ± 43.298 |
The Unified Parkinson's Disease Rating Scale (UPDRS) Part II is a scale for the assessment of function in Parkinson's disease. UPDRS Part II measures Activities of Daily Living. It consists of 13 questions, each ranging from 0 to 4. The sum score of the UPDRS Part II ranges from 0 to 52. A higher score indicates greater disability. A negative change score indicates improvement.
| units on a scale | Rotigotine 2 mg/24 hr | Rotigotine 4 mg/24 hr | Rotigotine 6 mg/24 hr | Rotigotine 8 mg/24 hr | Placebo |
|---|---|---|---|---|---|
| The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II From Baseline to the End of the Maintenance Period | -2.1 ± 4.3 | -2.2 ± 3.9 | -1.5 ± 4.7 | -2.1 ± 4.6 | -0.9 ± 3.7 |
The Unified Parkinson's Disease Rating Scale (UPDRS) Part III is a scale for the assessment of function in Parkinson's disease. UPDRS Part III measures Motor Function. It consists of 14 items with 27 questions, each ranging from 0 to 4. The sum score for the UPDRS Part III ranges from 0 to 108. A higher score indicates greater disability. A negative change score indicates improvement.
| units on a scale | Rotigotine 2 mg/24 hr | Rotigotine 4 mg/24 hr | Rotigotine 6 mg/24 hr | Rotigotine 8 mg/24 hr | Placebo |
|---|---|---|---|---|---|
| The Change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III From Baseline to the End of the Maintenance Period | -3.4 ± 7.6 | -4.5 ± 7.5 | -3.5 ± 8.9 | -5.9 ± 7.6 | -2.5 ± 8.2 |
Item = Duration (question #32) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period - What proportion of the waking day are dyskinesias present? Has a possible score of 0 - 4 points (4 = maximum). A higher score indicates more severe symptoms. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.
| participants | Rotigotine 2 mg/24 hr | Rotigotine 4 mg/24 hr | Rotigotine 6 mg/24 hr | Rotigotine 8 mg/24 hr | Placebo |
|---|---|---|---|---|---|
| Worsening | 15 | 14 | 13 | 15 | 12 |
| Equal | 74 | 72 | 75 | 69 | 84 |
| Improvement | 8 | 15 | 10 | 10 | 9 |
Item = Disability (question #33) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period - How disabling are the dyskinesias? Has a possible score of 0 - 4 points (4 = maximum). A higher score indicates more severe symptoms. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.
| participants | Rotigotine 2 mg/24 hr | Rotigotine 4 mg/24 hr | Rotigotine 6 mg/24 hr | Rotigotine 8 mg/24 hr | Placebo |
|---|---|---|---|---|---|
| Worsening | 7 | 6 | 2 | 6 | 9 |
| Equal | 80 | 89 | 86 | 78 | 90 |
| Improvement | 10 | 6 | 10 | 10 | 6 |
Item = Painful Dyskinesia (question #34) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period - How painful are the dyskinesias? Has a possible score of 0 - 4 points (4 = maximum). A higher score indicates more severe symptoms. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.
| participants | Rotigotine 2 mg/24 hr | Rotigotine 4 mg/24 hr | Rotigotine 6 mg/24 hr | Rotigotine 8 mg/24 hr | Placebo |
|---|---|---|---|---|---|
| Worsening | 2 | 3 | 4 | 2 | 8 |
| Equal | 90 | 94 | 86 | 87 | 94 |
| Improvement | 5 | 4 | 8 | 5 | 3 |
Item = Presence of Early Morning Dystonia (question #35) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates early morning dystonia. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.
| participants | Rotigotine 2 mg/24 hr | Rotigotine 4 mg/24 hr | Rotigotine 6 mg/24 hr | Rotigotine 8 mg/24 hr | Placebo |
|---|---|---|---|---|---|
| Worsening | 5 | 9 | 7 | 6 | 14 |
| Equal | 81 | 79 | 78 | 76 | 82 |
| Improvement | 11 | 13 | 13 | 12 | 9 |
Item = Are "off" periods predictable (question #36) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates "off" periods are predictable. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.
| participants | Rotigotine 2 mg/24 hr | Rotigotine 4 mg/24 hr | Rotigotine 6 mg/24 hr | Rotigotine 8 mg/24 hr | Placebo |
|---|---|---|---|---|---|
| Worsening | 6 | 4 | 12 | 3 | 11 |
| Equal | 80 | 82 | 74 | 80 | 85 |
| Improvement | 11 | 15 | 12 | 11 | 9 |
Item = Are "off" periods unpredictable (question #37) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates "off" periods are unpredictable. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.
| participants | Rotigotine 2 mg/24 hr | Rotigotine 4 mg/24 hr | Rotigotine 6 mg/24 hr | Rotigotine 8 mg/24 hr | Placebo |
|---|---|---|---|---|---|
| Worsening | 15 | 12 | 8 | 8 | 12 |
| Equal | 71 | 78 | 73 | 75 | 77 |
| Improvement | 11 | 11 | 17 | 11 | 16 |
Item = Do "off" periods come on suddenly, within a few seconds (question #38) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates "off" periods come on suddenly, within a few seconds. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.
| participants | Rotigotine 2 mg/24 hr | Rotigotine 4 mg/24 hr | Rotigotine 6 mg/24 hr | Rotigotine 8 mg/24 hr | Placebo |
|---|---|---|---|---|---|
| Worsening | 6 | 7 | 11 | 9 | 15 |
| Equal | 80 | 83 | 75 | 67 | 75 |
| Improvement | 11 | 11 | 12 | 18 | 15 |
Item = What proportion of the waking day is the subject "off", on average (question #39) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 - 4 points (4 = maximum). A higher score indicates the subject is "off" a larger portion of the waking day. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.
| participants | Rotigotine 2 mg/24 hr | Rotigotine 4 mg/24 hr | Rotigotine 6 mg/24 hr | Rotigotine 8 mg/24 hr | Placebo |
|---|---|---|---|---|---|
| Worsening | 8 | 4 | 8 | 7 | 11 |
| Equal | 52 | 58 | 58 | 55 | 61 |
| Improvement | 37 | 39 | 32 | 32 | 33 |
Item = Does the patient have anorexia, nausea, or vomiting (question #40) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates subject has anorexia, nausea, or vomiting. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.
| participants | Rotigotine 2 mg/24 hr | Rotigotine 4 mg/24 hr | Rotigotine 6 mg/24 hr | Rotigotine 8 mg/24 hr | Placebo |
|---|---|---|---|---|---|
| Worsening | 4 | 2 | 3 | 5 | 3 |
| Equal | 88 | 96 | 90 | 85 | 96 |
| Improvement | 5 | 3 | 5 | 4 | 6 |
Item = Does the patient have any sleep disturbances such as insomnia or hypersomnolence (question #41) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates subject has sleep disturbances such as insomnia or hypersomnolence. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.
| participants | Rotigotine 2 mg/24 hr | Rotigotine 4 mg/24 hr | Rotigotine 6 mg/24 hr | Rotigotine 8 mg/24 hr | Placebo |
|---|---|---|---|---|---|
| Worsening | 13 | 14 | 7 | 4 | 12 |
| Equal | 70 | 72 | 75 | 77 | 78 |
| Improvement | 14 | 15 | 16 | 13 | 15 |
Item = Does the patient have symptomatic orthostasis (question #42) in the Unified Parkinson's Disease Rating Scale (UPDRS) Part IV from Baseline to the end of the Maintenance Period has a possible score of 0 (no) or 1 (yes). A score of 1 indicates subject has symptomatic orthostasis. Results show the number of subjects per dose group and their change over time either improving (decrease in score), worsening (increase in score), or remaining the same.
| participants | Rotigotine 2 mg/24 hr | Rotigotine 4 mg/24 hr | Rotigotine 6 mg/24 hr | Rotigotine 8 mg/24 hr | Placebo |
|---|---|---|---|---|---|
| Worsening | 0 | 6 | 2 | 4 | 8 |
| Equal | 91 | 93 | 92 | 88 | 91 |
| Improvement | 6 | 2 | 4 | 2 | 6 |
Time "Off" is defined as when the patient does not have the effect of anti-Parkinson's medication.
| Hours | Rotigotine 2 mg/24 hr | Rotigotine 4 mg/24 hr | Rotigotine 6 mg/24 hr | Rotigotine 8 mg/24 hr | Placebo |
|---|---|---|---|---|---|
| The Change in Number of "Off" Periods From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary | -1.144 ± 1.687 | -1.294 ± 1.971 | -1.323 ± 1.348 | -1.304 ± 1.442 | -1.006 ± 1.474 |
Collected over Adverse Events (AEs) were collected during the course of the trial, which was approximately 33 weeks per subject.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rotigotine 2 mg/24 hr | — | 4/101 (4%) | 54/101 (53.5%) |
| Rotigotine 4 mg/24 hr | — | 3/107 (2.8%) | 54/107 (50.5%) |
| Rotigotine 6 mg/24 hr | — | 2/104 (1.9%) | 49/104 (47.1%) |
| Rotigotine 8 mg/24 hr | — | 0/94 (0%) | 52/94 (55.3%) |
| Placebo | — | 5/108 (4.6%) | 54/108 (50%) |
| Event | Rotigotine 2 mg/24 hr | Rotigotine 4 mg/24 hr | Rotigotine 6 mg/24 hr | Rotigotine 8 mg/24 hr | Placebo |
|---|---|---|---|---|---|
| Bundle branch block leftCardiac disorders | 1/101 | 0/107 | 0/104 | 0/94 | 0/108 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/101 | 0/107 | 0/104 | 0/94 | 0/108 |
| OrchitisInfections and infestations | 1/101 | 0/107 | 0/104 | 0/94 | 0/108 |
| Mental status changesPsychiatric disorders | 1/101 | 0/107 | 0/104 | 0/94 | 0/108 |
| Pneumonia aspirationRespiratory, thoracic and mediastinal disorders | 1/101 | 0/107 | 0/104 | 0/94 | 0/108 |
| Acetabulum fractureInjury, poisoning and procedural complications | 1/101 | 0/107 | 0/104 | 0/94 | 0/108 |
| Pubic rami fractureInjury, poisoning and procedural complications | 1/101 | 0/107 | 0/104 | 0/94 | 0/108 |
| FallInjury, poisoning and procedural complications | 0/101 | 1/107 | 1/104 | 0/94 | 0/108 |
| Brain herniationInjury, poisoning and procedural complications | 0/101 | 0/107 | 1/104 | 0/94 | 0/108 |
| Head injuryInjury, poisoning and procedural complications | 0/101 | 0/107 | 1/104 | 0/94 | 0/108 |
| Event | Rotigotine 2 mg/24 hr | Rotigotine 4 mg/24 hr | Rotigotine 6 mg/24 hr | Rotigotine 8 mg/24 hr | Placebo |
|---|---|---|---|---|---|
| DyskinesiaNervous system disorders | 5/101 | 4/107 | 11/104 | 14/94 | 3/108 |
| NauseaGastrointestinal disorders | 13/101 | 11/107 | 15/104 | 11/94 | 8/108 |
| HeadacheNervous system disorders | 10/101 | 8/107 | 6/104 | 8/94 | 12/108 |
| DizzinessNervous system disorders | 8/101 | 11/107 | 7/104 | 6/94 | 9/108 |
| SomnolenceNervous system disorders | 7/101 | 6/107 | 8/104 | 4/94 | 9/108 |
| ConstipationGastrointestinal disorders | 1/101 | 4/107 | 8/104 | 4/94 | 8/108 |
| Application site pruritusGeneral disorders | 4/101 | 6/107 | 8/104 | 7/94 | 2/108 |
| InsomniaPsychiatric disorders | 6/101 | 8/107 | 6/104 | 6/94 | 7/108 |
| FatigueGeneral disorders | 7/101 | 5/107 | 2/104 | 4/94 | 6/108 |
| Urinary tract infectionInfections and infestations | 7/101 | 2/107 | 2/104 | 1/94 | 4/108 |
| Age, Categorical(Participants) | Rotigotine 2 mg/24 hr | Rotigotine 4 mg/24 hr | Rotigotine 6 mg/24 hr | Rotigotine 8 mg/24 hr | Placebo | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 46 | 54 | 47 | 49 | 48 | 244 |
| >=65 years | 55 | 53 | 57 | 45 | 60 | 270 |
| Age, Continuous(years) | Rotigotine 2 mg/24 hr | Rotigotine 4 mg/24 hr | Rotigotine 6 mg/24 hr | Rotigotine 8 mg/24 hr | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 65.4 ± 10.5 | 64.6 ± 9.0 | 64.6 ± 10.4 | 63.2 ± 11.6 | 64.8 ± 10.2 | 64.5 ± 10.3 |
| Sex: Female, Male(Participants) | Rotigotine 2 mg/24 hr | Rotigotine 4 mg/24 hr | Rotigotine 6 mg/24 hr | Rotigotine 8 mg/24 hr | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 24 | 28 | 31 | 38 | 34 | 155 |
| Male | 77 | 79 | 73 | 56 | 74 | 359 |
| Region of Enrollment(participants) | Rotigotine 2 mg/24 hr | Rotigotine 4 mg/24 hr | Rotigotine 6 mg/24 hr | Rotigotine 8 mg/24 hr | Placebo | Total |
|---|---|---|---|---|---|---|
| United States | 66 | 72 | 68 | 59 | 69 | 334 |
| Mexico | 1 | 1 | 2 | 0 | 1 | 5 |
| Peru | 4 | 3 | 2 | 4 | 3 | 16 |
| Chile | 2 | 2 | 1 | 2 | 2 | 9 |
| India | 28 | 29 | 31 | 29 | 33 | 150 |
The record gives a start of Jul 2007, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2012, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine